ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
PO Box 28,
South Australia 5007
North Terrace House,
19 North Terrace,
Hackney, SA, 5069
1300 128 339
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
New CBD Patches Combat Nerve Pain And Fibromyalgia
Tuesday 8 November 2016
New CBD Patches Combat Nerve Pain and Fibromyalgia
Although cannabis is still considered to have no medical use by the Drug Enforcement Administration, pharmaceutical companies continue to create medications that prove its efficacy against countless ailments. Cannabis Science, Inc. has developed two new pain relief patches that are specifically for patients with Diabetic Neuropathy nerve pain and Fibromyalgia.
Fibromyalgia is a medical condition in which the individual experiences chronic widespread pain and a higher, more painful response to pressure. Neuropathy damages or spreads disease to nerves and can have various painful effects depending on which nerves are affected. Now patients facing either of these ailments might find relief with the transdermal CBD patches created by Cannabis Science.
The transdermal pads are made with high potency cannabinoid (CBD) extract. The extract is released in a controlled fashion, which enters into the bloodstream through a medicated adhesive patch that is put on the skin. The CBD extract enters through the skin and into the central nervous system, which is how patients receive pain relief.
blog comments powered by Disqus